1:"$Sreact.fragment"
2:I[22016,["/rigidbodydynamicsai/_next/static/chunks/8461251ea68c7ff3.js"],""]
6d:I[97367,["/rigidbodydynamicsai/_next/static/chunks/ff1a16fafef87110.js","/rigidbodydynamicsai/_next/static/chunks/d2be314c3ece3fbe.js"],"OutletBoundary"]
6e:"$Sreact.suspense"
0:{"buildId":"8nmnW_8LUcQxaBO0rEWXk","rsc":["$","$1","c",{"children":[["$","div",null,{"className":"min-h-screen bg-white text-foreground","children":["$","main",null,{"className":"mx-auto max-w-3xl px-6 pt-28 pb-24","children":[["$","nav",null,{"className":"mb-10 flex items-center gap-2 text-xs text-neutral-400","children":[["$","$L2",null,{"href":"/","className":"hover:text-neutral-600 transition-colors","children":"Home"}],["$","span",null,{"children":"/"}],["$","$L2",null,{"href":"/research","className":"hover:text-neutral-600 transition-colors","children":"Research"}],["$","span",null,{"children":"/"}],["$","$L2",null,{"href":"/reports/market-opportunity-research","className":"hover:text-neutral-600 transition-colors","children":"AI Market Opportunity Research"}],["$","span",null,{"children":"/"}],["$","span",null,{"className":"text-neutral-500","children":"Clinical Trial Patient Recruitment Failure"}]]}],["$","p",null,{"className":"mb-3 text-xs font-medium uppercase tracking-widest text-neutral-400","children":"Sub-research Â· February 2026"}],["$","article",null,{"className":"prose-report markdown-report","children":[["$","h1","h1-0",{"className":"text-3xl font-semibold leading-tight tracking-tight text-neutral-900 sm:text-4xl mt-0 mb-4","children":"Clinical Trial Patient Recruitment Failure"}],"\n",["$","h2","h2-0",{"className":"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28","children":"Problem Statement"}],"\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"80% of clinical trials are delayed due to poor patient recruitment. Sponsors lose approximately $8M per day per delayed trial. Sites manually screen thousands of charts to find eligible patients, creating a massive bottleneck in drug development timelines."}],"\n",["$","p","p-1",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Who Suffers:"}]," Pharmaceutical sponsors (VP Clinical Operations, Head of Patient Recruitment), CROs (project managers, site feasibility teams), and clinical trial sites (principal investigators, study coordinators)."]}],"\n",["$","hr","hr-0",{"className":"my-8 border-neutral-100"}],"\n",["$","h2","h2-1",{"className":"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28","children":"1. PROBLEM MARKET SIZE"}],"\n",["$","p","p-2",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Total annual cost of the recruitment failure problem: $30B--$50B+ per year"}]}],"\n",["$","div","table-0",{"className":"my-6 overflow-x-auto rounded-lg border border-neutral-200","children":["$","table",null,{"className":"w-full text-sm","children":[["$","thead","thead-0",{"className":"border-b border-neutral-200 bg-neutral-50","children":["$","tr","tr-0",{"className":"bg-white","children":[["$","th","th-0",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Metric"}],["$","th","th-1",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Value"}],["$","th","th-2",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Source"}]]}]}],["$","tbody","tbody-0",{"className":"divide-y divide-neutral-100","children":[["$","tr","tr-0",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Cost per day of trial delay (avg)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$600K -- $8M/day depending on phase and therapeutic area"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Tufts CSDD (2018, reaffirmed in 2023 analyses); Cutting Edge Information"}]]}],["$","tr","tr-1",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Average trial delay from recruitment"}],"$L3","$L4"]}],"$L5","$L6","$L7","$L8","$L9"]}]]}]}],"\n","$La","\n","$Lb","\n","$Lc","\n","$Ld","\n","$Le","\n","$Lf","\n","$L10","\n","$L11","\n","$L12","\n","$L13","\n","$L14","\n","$L15","\n","$L16","\n","$L17","\n","$L18","\n","$L19","\n","$L1a","\n","$L1b","\n","$L1c","\n","$L1d","\n","$L1e","\n","$L1f","\n","$L20","\n","$L21","\n","$L22","\n","$L23","\n","$L24","\n","$L25","\n","$L26","\n","$L27","\n","$L28","\n","$L29","\n","$L2a","\n","$L2b","\n","$L2c","\n","$L2d","\n","$L2e","\n","$L2f","\n","$L30","\n","$L31","\n","$L32","\n","$L33","\n","$L34","\n","$L35","\n","$L36","\n","$L37","\n","$L38","\n","$L39","\n","$L3a","\n","$L3b","\n","$L3c","\n","$L3d","\n","$L3e","\n","$L3f","\n","$L40","\n","$L41","\n","$L42","\n","$L43","\n","$L44","\n","$L45","\n","$L46","\n","$L47","\n","$L48","\n","$L49","\n","$L4a","\n","$L4b","\n","$L4c","\n","$L4d","\n","$L4e","\n","$L4f","\n","$L50","\n","$L51","\n","$L52","\n","$L53","\n","$L54"]}],"$L55"]}]}],null,"$L56"]}],"loading":null,"isPartial":false}
3:["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"6 months"}]
4:["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"CISCRP / Tufts CSDD"}]
5:["$","tr","tr-2",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"% of trials delayed by recruitment"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"80%"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"GAO Report; Tufts CSDD"}]]}]
6:["$","tr","tr-3",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Total R&D spend by pharma annually"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~$250B globally (2024)"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"IQVIA Institute; Evaluate Pharma"}]]}]
7:["$","tr","tr-4",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Recruitment-related share of R&D waste"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"12--20%"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Deloitte Life Sciences; McKinsey"}]]}]
8:["$","tr","tr-5",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Lost revenue from delayed drug approvals"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$1M--$8M/day in foregone peak sales per day of delay"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Tufts CSDD; KMR Group"}]]}]
9:["$","tr","tr-6",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Estimated total annual cost of trial delays (recruitment-driven)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$30B--$50B"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Derived: ~45,000 interventional trials x 80% delayed x avg 5.5 month delay x avg $1.5M--$3M/month cost"}]]}]
a:["$","p","p-3",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Key data points:"}]}]
b:["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Tufts CSDD estimates the average cost to develop a new drug at $2.6B (updated to ~$2.9B by 2024 estimates), with clinical trial execution being the largest single cost driver (~60--70% of total)."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"The \"opportunity cost\" of a one-day delay in bringing a blockbuster drug to market ranges from $600K/day (niche drugs) to $8M+/day (oncology blockbusters with $3B+ peak annual sales)."}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"IQVIA's 2024 Global Trends in R&D report noted that clinical trial durations have increased 25% over the past decade, with recruitment being the primary driver."}],"\n"]}]
c:["$","hr","hr-1",{"className":"my-8 border-neutral-100"}]
d:["$","h2","h2-2",{"className":"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28","children":"2. CURRENT SPEND TO MANAGE"}]
e:["$","p","p-4",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Companies currently spend $15B--$20B+ annually on recruitment-related services and technology."}]}]
f:["$","div","table-1",{"className":"my-6 overflow-x-auto rounded-lg border border-neutral-200","children":["$","table",null,{"className":"w-full text-sm","children":[["$","thead","thead-0",{"className":"border-b border-neutral-200 bg-neutral-50","children":["$","tr","tr-0",{"className":"bg-white","children":[["$","th","th-0",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Market Segment"}],["$","th","th-1",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Size (2024)"}],["$","th","th-2",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"CAGR"}],["$","th","th-3",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Source"}]]}]}],["$","tbody","tbody-0",{"className":"divide-y divide-neutral-100","children":[["$","tr","tr-0",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Clinical Trial Patient Recruitment & Retention Services"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$2.5B--$3.0B"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"6.5--7.2%"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Grand View Research (2024); Allied Market Research"}]]}],["$","tr","tr-1",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Patient Matching / AI Screening Software"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$800M--$1.2B"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"14--18%"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"MarketsandMarkets; Mordor Intelligence"}]]}],["$","tr","tr-2",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Contract Research Organization (CRO) Market (total)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$82B--$90B (2024)"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"7.5--8.5%"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Grand View Research; Fortune Business Insights"}]]}],["$","tr","tr-3",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"CRO recruitment-specific allocation (~15-20% of CRO spend)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$12B--$18B"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~8%"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Industry estimates; IQVIA"}]]}],["$","tr","tr-4",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Site Management Organizations (SMOs)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$4B--$5B"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"6--8%"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Mordor Intelligence"}]]}],["$","tr","tr-5",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Electronic Data Capture + Clinical Trial Management Systems"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$8B--$10B"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"12--14%"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"MarketsandMarkets"}]]}],["$","tr","tr-6",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Digital patient recruitment (social, digital ads, decentralized)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$1.5B--$2.0B"}],"$L57","$L58"]}]]}]]}]}]
10:["$","p","p-5",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"What sponsors actually spend on recruitment per trial:"}]}]
11:["$","ul","ul-1",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Average recruitment cost per trial: $1.5M--$5M (Phase II); $5M--$20M+ (Phase III)"}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Per-patient recruitment cost: $3,000--$7,000 (Phase II); $7,000--$15,000+ (Phase III oncology)"}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Sites receive $20,000--$100,000+ per enrolled patient depending on therapeutic area and phase"}],"\n"]}]
12:["$","hr","hr-2",{"className":"my-8 border-neutral-100"}]
13:["$","h2","h2-3",{"className":"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28","children":"3. COST OF INACTION"}]
14:["$","div","table-2",{"className":"my-6 overflow-x-auto rounded-lg border border-neutral-200","children":["$","table",null,{"className":"w-full text-sm","children":[["$","thead","thead-0",{"className":"border-b border-neutral-200 bg-neutral-50","children":["$","tr","tr-0",{"className":"bg-white","children":[["$","th","th-0",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Consequence"}],["$","th","th-1",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Quantified Impact"}],["$","th","th-2",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Source"}]]}]}],["$","tbody","tbody-0",{"className":"divide-y divide-neutral-100","children":[["$","tr","tr-0",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Cost per day of Phase III trial delay"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$600K--$8M/day"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Tufts CSDD; Cutting Edge Information"}]]}],["$","tr","tr-1",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Protocol amendments due to recruitment failure"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Avg 2.3 amendments per trial; each costs $500K--$1M+"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Tufts CSDD (2023 update)"}]]}],["$","tr","tr-2",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Trials that fail to meet enrollment targets"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"19% of trials terminated early; 80%+ delayed"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"ClinicalTrials.gov analysis; FDA"}]]}],["$","tr","tr-3",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Extension of patent exclusivity window consumed by delays"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"1--3 years of effective patent life lost"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"KMR Group; Evaluate Pharma"}]]}],["$","tr","tr-4",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Impact on FDA approval timeline"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Avg 8--14 months delay to NDA/BLA submission"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Tufts CSDD"}]]}],["$","tr","tr-5",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Revenue lost per year of delay (blockbuster)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$1B--$3B in foregone sales"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Deloitte Life Sciences"}]]}],["$","tr","tr-6",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Site dropout from slow-enrolling trials"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"11% of sites enroll zero patients"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Tufts CSDD; KMR Group"}]]}],["$","tr","tr-7",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Increased screen failure rates"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"25--50% of screened patients fail (wasted cost)"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"CISCRP"}]]}],["$","tr","tr-8",{"className":"bg-white","children":["$L59","$L5a","$L5b"]}]]}]]}]}]
15:["$","p","p-6",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Cascade effects:"}]}]
16:["$","ul","ul-2",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Failed recruitment forces protocol amendments (adding sites, loosening criteria), each costing $500K--$1M and adding 3--6 months."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"37% of study sites under-enroll, forcing sponsors to activate 2--3x more sites than originally planned."}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Every month of delay erodes the effective patent exclusivity window -- for a drug with $2B peak annual sales, each month of delay costs approximately $167M in lost exclusive-market revenue."}],"\n"]}]
17:["$","hr","hr-3",{"className":"my-8 border-neutral-100"}]
18:["$","h2","h2-4",{"className":"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28","children":"4. VOLUME FREQUENCY"}]
19:["$","div","table-3",{"className":"my-6 overflow-x-auto rounded-lg border border-neutral-200","children":["$","table",null,{"className":"w-full text-sm","children":[["$","thead","thead-0",{"className":"border-b border-neutral-200 bg-neutral-50","children":["$","tr","tr-0",{"className":"bg-white","children":[["$","th","th-0",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Metric"}],["$","th","th-1",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Value"}],["$","th","th-2",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Source"}]]}]}],["$","tbody","tbody-0",{"className":"divide-y divide-neutral-100","children":[["$","tr","tr-0",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Active interventional trials globally (2024)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~45,000--50,000"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"ClinicalTrials.gov (2024); WHO ICTRP"}]]}],["$","tr","tr-1",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"New trials registered annually"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~15,000--17,000 interventional trials/year"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"ClinicalTrials.gov (2024 data)"}]]}],["$","tr","tr-2",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"% of trials delayed by enrollment"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"80%"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"GAO; Tufts CSDD"}]]}],["$","tr","tr-3",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"% of trials that fail to enroll a single patient at 1+ sites"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"48% of sites fail to meet targets; 11% enroll zero"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Tufts CSDD"}]]}],["$","tr","tr-4",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Screen-to-enroll ratio (avg)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"5:1 to 10:1 (general); up to 50:1 (rare disease/oncology)"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"CISCRP; IQVIA"}]]}],["$","tr","tr-5",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Charts manually reviewed per enrolled patient"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"50--200 charts per site per study (depending on indication)"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Site coordinator surveys; Tufts CSDD"}]]}],["$","tr","tr-6",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Number of eligibility criteria per trial (avg)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"31 criteria (up from 24 in 2008)"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Tufts CSDD (2023)"}]]}],["$","tr","tr-7",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Average enrollment period target vs. actual"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Target: 12 months; Actual: 19 months (avg 58% overrun)"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Citeline Trialtrove"}]]}],["$","tr","tr-8",{"className":"bg-white","children":["$L5c","$L5d","$L5e"]}],"$L5f","$L60"]}]]}]}]
1a:["$","p","p-7",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Scale illustration:"}]}]
1b:["$","ul","ul-3",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"A typical Phase III oncology trial needs 500--1,500 patients across 100--300 sites globally."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"To enroll 1,000 patients with a 10:1 screen ratio, sites must collectively review ~10,000 patient charts."}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"With 31 eligibility criteria on average, each chart review takes 30--60 minutes, totaling 5,000--10,000 person-hours of manual screening per trial."}],"\n"]}]
1c:["$","hr","hr-4",{"className":"my-8 border-neutral-100"}]
1d:["$","h2","h2-5",{"className":"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28","children":"5. WHY STILL UNSOLVED"}]
1e:["$","h3","h3-0",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"5.1 EHR Fragmentation"}]
1f:["$","ul","ul-4",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"US healthcare runs on 700+ distinct EHR systems; Epic and Cerner/Oracle Health cover ~60% of hospital beds, but data formats, coding standards, and accessibility vary enormously."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Even within Epic, individual health system instances are configured differently, making cross-system patient queries extremely difficult."}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"FHIR interoperability standards (21st Century Cures Act) are improving data access but adoption remains incomplete; many community hospitals and private practices lag."}],"\n"]}]
20:["$","h3","h3-1",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"5.2 Data Quality and Standardization"}]
21:["$","ul","ul-5",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Clinical trial eligibility criteria are written in free text (protocol documents), not structured queries. Translating \"no clinically significant cardiac arrhythmia\" into a computable EHR query is non-trivial."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Lab values, diagnosis codes, medication histories, and procedure records are stored inconsistently across institutions."}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Unstructured clinical notes contain critical eligibility information (e.g., performance status, disease staging) that is not captured in structured fields."}],"\n"]}]
22:["$","h3","h3-2",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"5.3 Regulatory and Privacy Constraints"}]
23:["$","ul","ul-6",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"HIPAA restricts proactive outreach to patients without prior consent or an existing treatment relationship."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"IRB requirements add 4--8 weeks before sites can begin screening."}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"EU GDPR and country-specific regulations further complicate cross-border patient identification."}],"\n",["$","li","li-3",{"className":"leading-relaxed","children":"The Common Rule and 21 CFR Part 50 require informed consent processes that add friction."}],"\n"]}]
24:["$","h3","h3-3",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"5.4 Site Capacity and Incentive Misalignment"}]
25:["$","ul","ul-7",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"70% of trial sites are community-based practices with limited research infrastructure."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Study coordinators are overworked (managing 3--8 trials simultaneously) and under-resourced."}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Sites are paid per enrolled patient, creating incentive to over-promise and under-deliver on recruitment timelines."}],"\n",["$","li","li-3",{"className":"leading-relaxed","children":"High coordinator turnover (~30% annually) means institutional knowledge is constantly lost."}],"\n"]}]
26:["$","h3","h3-4",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"5.5 Protocol Complexity Growth"}]
27:["$","ul","ul-8",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Average eligibility criteria per trial increased from 24 (2008) to 31+ (2023) per Tufts CSDD."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Complex protocols with biomarker requirements, genetic testing, and washout periods narrow the eligible population dramatically."}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Oncology trials with molecular targets may have <5% of cancer patients eligible."}],"\n"]}]
28:["$","h3","h3-5",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"5.6 Patient Awareness and Access"}]
29:["$","ul","ul-9",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"85% of patients are unaware that clinical trials are an option for their condition (CISCRP 2023)."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Minority and underserved populations are systematically under-represented due to site locations (concentrated in academic medical centers), transportation barriers, and historical distrust."}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"FDA now mandates diversity action plans (2024), adding a new recruitment dimension."}],"\n"]}]
2a:["$","h3","h3-6",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"5.7 Incumbent Technology Limitations"}]
2b:["$","ul","ul-10",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"CTMS (Clinical Trial Management Systems) track enrollment but do not find patients."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Existing patient matching tools (e.g., TriNetX, Tempus) require health systems to opt in and share data -- coverage is partial."}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"AI/NLP tools for chart screening exist but face validation/regulatory acceptance barriers."}],"\n",["$","li","li-3",{"className":"leading-relaxed","children":"No single platform connects EHR data + trial protocols + patient consent + site capacity in real-time."}],"\n"]}]
2c:["$","hr","hr-5",{"className":"my-8 border-neutral-100"}]
2d:["$","h2","h2-6",{"className":"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28","children":"6. WILLINGNESS TO PAY SIGNALS"}]
2e:["$","h3","h3-7",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"6.1 Current Spending on Recruitment Services"}]
2f:["$","ul","ul-11",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Top 20 pharma companies spend $500M--$2B+ each annually on clinical operations, with 15--25% allocated to recruitment."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Per-patient recruitment costs: $3,000 (simple Phase I) to $50,000+ (rare disease, oncology biomarker-selected)."}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"Sponsors routinely pay $30,000--$100,000 per site activation fee regardless of enrollment success."}],"\n"]}]
30:["$","h3","h3-8",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"6.2 VC Funding in Trial Recruitment Tech (2023--2025)"}]
31:["$","div","table-4",{"className":"my-6 overflow-x-auto rounded-lg border border-neutral-200","children":["$","table",null,{"className":"w-full text-sm","children":[["$","thead","thead-0",{"className":"border-b border-neutral-200 bg-neutral-50","children":["$","tr","tr-0",{"className":"bg-white","children":[["$","th","th-0",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Company"}],["$","th","th-1",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Funding"}],["$","th","th-2",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Year"}],["$","th","th-3",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Focus"}]]}]}],["$","tbody","tbody-0",{"className":"divide-y divide-neutral-100","children":[["$","tr","tr-0",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Antidote Technologies (acq. by Komodo Health)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Acquired"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"2023"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Patient matching for trials"}]]}],["$","tr","tr-1",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Triomics"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$15M Series A"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"2024"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"AI for oncology trial matching"}]]}],["$","tr","tr-2",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Massive Bio"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$20M+"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"2023--2024"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"AI clinical trial matching (oncology)"}]]}],["$","tr","tr-3",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Deep 6 AI"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$17M Series A"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"2021--2023"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"NLP-based patient-trial matching"}]]}],["$","tr","tr-4",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Tempus"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$6.1B valuation (IPO 2024)"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"2024"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Genomic data + trial matching"}]]}],["$","tr","tr-5",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Flatiron Health (Roche)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Acquired for $1.9B"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"2018 (ongoing investment)"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Oncology real-world data + trial matching"}]]}],["$","tr","tr-6",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Medable"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$304M total funding"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"2021--2023"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Decentralized trials"}]]}],["$","tr","tr-7",{"className":"bg-white","children":["$L61","$L62","$L63","$L64"]}],"$L65","$L66"]}]]}]}]
32:["$","p","p-8",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Total VC investment in clinical trial tech (broadly): $2B--$3B annually (2023--2024)"}]}]
33:["$","h3","h3-9",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"6.3 Budget Signals"}]
34:["$","ul","ul-12",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Pharma companies are creating dedicated \"Patient Centricity\" and \"Digital Recruitment\" roles (VP level) -- signal of strategic priority."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"CROs (Parexel, IQVIA, PPD/Thermo Fisher) all launched dedicated AI recruitment platforms in 2023--2024."}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"FDA's 2024 diversity guidance is forcing sponsors to budget separately for diverse enrollment, creating new spend."}],"\n"]}]
35:["$","h3","h3-10",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"6.4 Contract Values"}]
36:["$","ul","ul-13",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Large pharma-CRO recruitment partnerships: $50M--$200M multi-year contracts."}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"TriNetX subscription pricing: $200K--$500K/year per health system; $500K--$2M/year per pharma sponsor."}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"IQVIA site feasibility and recruitment solutions: $1M--$5M per engagement."}],"\n"]}]
37:["$","hr","hr-6",{"className":"my-8 border-neutral-100"}]
38:["$","h2","h2-7",{"className":"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28","children":"7. MARKET GROWTH RATE"}]
39:["$","div","table-5",{"className":"my-6 overflow-x-auto rounded-lg border border-neutral-200","children":["$","table",null,{"className":"w-full text-sm","children":[["$","thead","thead-0",{"className":"border-b border-neutral-200 bg-neutral-50","children":["$","tr","tr-0",{"className":"bg-white","children":[["$","th","th-0",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Segment"}],["$","th","th-1",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"CAGR (2024--2030)"}],["$","th","th-2",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Drivers"}]]}]}],["$","tbody","tbody-0",{"className":"divide-y divide-neutral-100","children":[["$","tr","tr-0",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Clinical Trial Patient Recruitment Services"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"6.5--7.2%"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Growing trial complexity, decentralized trials"}]]}],["$","tr","tr-1",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"AI-Powered Patient Matching Software"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"14--18%"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"NLP/AI advances, EHR interoperability, FDA guidance"}]]}],["$","tr","tr-2",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Decentralized/Virtual Clinical Trials"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"17--20%"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Post-COVID momentum, regulatory acceptance"}]]}],["$","tr","tr-3",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"CRO Market (total)"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"7.5--8.5%"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Pharma outsourcing trend, biosimilar trials"}]]}],["$","tr","tr-4",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Clinical Trial Management Systems"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"12--14%"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Digital transformation, cloud adoption"}]]}],["$","tr","tr-5",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Overall clinical trial technology market"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"11--13%"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Convergence of AI, real-world data, decentralization"}]]}]]}]]}]}]
3a:["$","p","p-9",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Key growth drivers:"}]}]
3b:["$","ul","ul-14",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":"Trial complexity increasing (more biomarker-driven, precision medicine trials)"}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"FDA diversity requirements creating new recruitment workstreams"}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":"AI/ML reaching production readiness for NLP-based chart screening"}],"\n",["$","li","li-3",{"className":"leading-relaxed","children":"21st Century Cures Act improving EHR data accessibility via FHIR APIs"}],"\n",["$","li","li-4",{"className":"leading-relaxed","children":"Decentralized trial models (post-COVID) expanding the recruitable patient pool"}],"\n"]}]
3c:["$","hr","hr-7",{"className":"my-8 border-neutral-100"}]
3d:["$","h2","h2-8",{"className":"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28","children":"8. KEY PLAYERS TODAY"}]
3e:["$","h3","h3-11",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Patient Matching and Recruitment Technology"}]
3f:["$","div","table-6",{"className":"my-6 overflow-x-auto rounded-lg border border-neutral-200","children":["$","table",null,{"className":"w-full text-sm","children":[["$","thead","thead-0",{"className":"border-b border-neutral-200 bg-neutral-50","children":["$","tr","tr-0",{"className":"bg-white","children":[["$","th","th-0",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Company"}],["$","th","th-1",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Description"}],["$","th","th-2",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Revenue/Valuation (est.)"}]]}]}],["$","tbody","tbody-0",{"className":"divide-y divide-neutral-100","children":[["$","tr","tr-0",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"TriNetX"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Federated health research network; 250M+ patient records across 170+ health systems globally"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Est. $150M--$200M ARR (private)"}]]}],["$","tr","tr-1",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"IQVIA"}]," (NYSE: IQV)"]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Largest CRO + health data company; trial design, site selection, patient recruitment"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$15.4B revenue (2024); recruitment/tech segment ~$3B"}]]}],["$","tr","tr-2",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Veeva Systems"}]," (NYSE: VEEV)"]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Clinical trial suite (Vault CTMS, eTMF, Site Connect)"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$2.36B revenue (FY2025); clinical data segment ~$400M"}]]}],["$","tr","tr-3",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Medidata"}]," (Dassault Systemes)"]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Clinical trial tech platform (Rave, Patient Cloud, Acorn AI)"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Est. $1.5B--$1.8B revenue (2024)"}]]}],["$","tr","tr-4",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Tempus AI"}]," (NASDAQ: TEM)"]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Genomic data + AI clinical trial matching (oncology focus)"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$693M revenue (2024); IPO valuation $6.1B"}]]}],["$","tr","tr-5",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Flatiron Health"}]," (Roche)"]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Oncology real-world data + trial matching"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Est. $400M--$500M revenue (within Roche)"}]]}],["$","tr","tr-6",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Komodo Health"}]," (acq. Antidote)"]}],"$L67","$L68"]}],"$L69","$L6a","$L6b","$L6c"]}]]}]}]
40:["$","h3","h3-12",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"CROs with Major Recruitment Capabilities"}]
41:["$","div","table-7",{"className":"my-6 overflow-x-auto rounded-lg border border-neutral-200","children":["$","table",null,{"className":"w-full text-sm","children":[["$","thead","thead-0",{"className":"border-b border-neutral-200 bg-neutral-50","children":["$","tr","tr-0",{"className":"bg-white","children":[["$","th","th-0",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Company"}],["$","th","th-1",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Revenue (2024)"}],["$","th","th-2",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Recruitment Focus"}]]}]}],["$","tbody","tbody-0",{"className":"divide-y divide-neutral-100","children":[["$","tr","tr-0",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"IQVIA"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$15.4B"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Technology + services integrated recruitment"}]]}],["$","tr","tr-1",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Labcorp Drug Development"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~$3.2B (drug dev segment)"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Site networks, patient databases"}]]}],["$","tr","tr-2",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"PPD (Thermo Fisher)"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~$5B (within Thermo Fisher)"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Accelerated enrollment, site networks"}]]}],["$","tr","tr-3",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Parexel"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~$2.5B (private, est.)"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"AI-enhanced feasibility and recruitment"}]]}],["$","tr","tr-4",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Syneos Health"}]," (acq. by Elliott)"]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~$5.3B (pre-acquisition)"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Integrated biopharmaceutical solutions"}]]}],["$","tr","tr-5",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Medpace"}]," (NASDAQ: MEDP)"]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$2.1B (2024)"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Full-service CRO with recruitment focus"}]]}],["$","tr","tr-6",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"ICON plc"}]," (NASDAQ: ICLR)"]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$8.3B (2024)"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Large-scale trial management"}]]}]]}]]}]}]
42:["$","h3","h3-13",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Decentralized Trial / Patient Engagement"}]
43:["$","div","table-8",{"className":"my-6 overflow-x-auto rounded-lg border border-neutral-200","children":["$","table",null,{"className":"w-full text-sm","children":[["$","thead","thead-0",{"className":"border-b border-neutral-200 bg-neutral-50","children":["$","tr","tr-0",{"className":"bg-white","children":[["$","th","th-0",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Company"}],["$","th","th-1",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Funding/Revenue"}],["$","th","th-2",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Focus"}]]}]}],["$","tbody","tbody-0",{"className":"divide-y divide-neutral-100","children":[["$","tr","tr-0",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Medable"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$304M raised"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Decentralized trial platform"}]]}],["$","tr","tr-1",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Science 37"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Public (SNCE); ~$60M revenue"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Virtual trial operations"}]]}],["$","tr","tr-2",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Thread (acquired by Labcorp)"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Acquired 2023"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Decentralized trial tech"}]]}],["$","tr","tr-3",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"ObvioHealth"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$32M raised"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Virtual/decentralized trials"}]]}]]}]]}]}]
44:["$","hr","hr-8",{"className":"my-8 border-neutral-100"}]
45:["$","h2","h2-9",{"className":"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28","children":"9. KEY SOURCES"}]
46:["$","p","p-10",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Note:"}]," WebSearch and WebFetch tools were unavailable during this research session. The following sources are cited from knowledge through May 2025. URLs are provided for verification; all data points should be confirmed against the original source for final use."]}]
47:["$","h3","h3-14",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Industry Research Centers"}]
48:["$","ol","ol-0",{"className":"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"Tufts Center for the Study of Drug Development (CSDD) -- Clinical trial cost and recruitment statistics"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["$","a","a-0",{"href":"https://csdd.tufts.edu/","children":"https://csdd.tufts.edu/"}]}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Key publications: \"Impact Reports\" on protocol complexity, site performance, recruitment metrics"}],"\n"]}],"\n"]}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"CISCRP (Center for Information and Study on Clinical Research Participation)"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["$","a","a-0",{"href":"https://www.ciscrp.org/","children":"https://www.ciscrp.org/"}]}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":"Perceptions and Insights Study (2023); recruitment awareness data"}],"\n"]}],"\n"]}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"IQVIA Institute for Human Data Science -- Global Trends in R&D (2024)"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["$","a","a-0",{"href":"https://www.iqvia.com/insights/the-iqvia-institute","children":"https://www.iqvia.com/insights/the-iqvia-institute"}]}],"\n"]}],"\n"]}],"\n"]}]
49:["$","h3","h3-15",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Market Research Reports"}]
4a:["$","ol","ol-1",{"className":"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"Grand View Research -- Patient Recruitment and Retention Services Market (2024)"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["$","a","a-0",{"href":"https://www.grandviewresearch.com/industry-analysis/patient-recruitment-retention-services-market","children":"https://www.grandviewresearch.com/industry-analysis/patient-recruitment-retention-services-market"}]}],"\n"]}],"\n"]}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"Grand View Research -- Contract Research Organization Market (2024)"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["$","a","a-0",{"href":"https://www.grandviewresearch.com/industry-analysis/contract-research-organization-cro-market","children":"https://www.grandviewresearch.com/industry-analysis/contract-research-organization-cro-market"}]}],"\n"]}],"\n"]}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"MarketsandMarkets -- Clinical Trial Management System Market (2024)"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["$","a","a-0",{"href":"https://www.marketsandmarkets.com/Market-Reports/clinical-trial-management-system-market","children":"https://www.marketsandmarkets.com/Market-Reports/clinical-trial-management-system-market"}]}],"\n"]}],"\n"]}],"\n",["$","li","li-3",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"Mordor Intelligence -- CRO Market Size and Share Analysis (2024)"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["$","a","a-0",{"href":"https://www.mordorintelligence.com/industry-reports/contract-research-organization-market","children":"https://www.mordorintelligence.com/industry-reports/contract-research-organization-market"}]}],"\n"]}],"\n"]}],"\n",["$","li","li-4",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"Allied Market Research -- Clinical Trial Patient Recruitment Services Market"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["$","a","a-0",{"href":"https://www.alliedmarketresearch.com/clinical-trial-patient-recruitment-services-market","children":"https://www.alliedmarketresearch.com/clinical-trial-patient-recruitment-services-market"}]}],"\n"]}],"\n"]}],"\n"]}]
4b:["$","h3","h3-16",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Government and Regulatory"}]
4c:["$","ol","ol-2",{"className":"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"ClinicalTrials.gov -- Trial registry and trends data"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["$","a","a-0",{"href":"https://clinicaltrials.gov/","children":"https://clinicaltrials.gov/"}]}],"\n"]}],"\n"]}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"GAO Report -- \"Drug Development: FDA Efforts to Address Challenges in Clinical Trials\""}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["$","a","a-0",{"href":"https://www.gao.gov/","children":"https://www.gao.gov/"}]}],"\n"]}],"\n"]}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"FDA Guidance on Diversity Action Plans for Clinical Studies (2024)"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["$","a","a-0",{"href":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents","children":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents"}]}],"\n"]}],"\n"]}],"\n"]}]
4d:["$","h3","h3-17",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Industry Analysis and Consulting"}]
4e:["$","ol","ol-3",{"className":"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"Deloitte -- \"Measuring the Return from Pharmaceutical Innovation\" (annual series)"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["$","a","a-0",{"href":"https://www2.deloitte.com/","children":"https://www2.deloitte.com/"}]}],"\n"]}],"\n"]}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"McKinsey & Company -- \"How to Improve Clinical Trial Recruitment\" (2023)"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["$","a","a-0",{"href":"https://www.mckinsey.com/industries/life-sciences","children":"https://www.mckinsey.com/industries/life-sciences"}]}],"\n"]}],"\n"]}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"KMR Group -- Clinical trial benchmarking data"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["$","a","a-0",{"href":"https://www.kmrgroup.com/","children":"https://www.kmrgroup.com/"}]}],"\n"]}],"\n"]}],"\n",["$","li","li-3",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"Citeline / Trialtrove -- Clinical trial intelligence database"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["$","a","a-0",{"href":"https://www.citeline.com/","children":"https://www.citeline.com/"}]}],"\n"]}],"\n"]}],"\n"]}]
4f:["$","h3","h3-18",{"className":"text-base font-medium text-neutral-800 mt-10 mb-3","children":"Company/Investor Sources"}]
50:["$","ol","ol-4",{"className":"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"Tempus AI S-1 Filing (IPO 2024) -- Revenue and clinical trial matching data"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["$","a","a-0",{"href":"https://www.sec.gov/cgi-bin/browse-edgar?company=tempus","children":"https://www.sec.gov/cgi-bin/browse-edgar?company=tempus"}]}],"\n"]}],"\n"]}],"\n",["$","li","li-1",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"IQVIA 2024 10-K Annual Report"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["$","a","a-0",{"href":"https://ir.iqvia.com/","children":"https://ir.iqvia.com/"}]}],"\n"]}],"\n"]}],"\n",["$","li","li-2",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"Veeva Systems FY2025 10-K Annual Report"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["$","a","a-0",{"href":"https://ir.veeva.com/","children":"https://ir.veeva.com/"}]}],"\n"]}],"\n"]}],"\n",["$","li","li-3",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"Medpace 2024 10-K Annual Report"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["$","a","a-0",{"href":"https://investor.medpace.com/","children":"https://investor.medpace.com/"}]}],"\n"]}],"\n"]}],"\n",["$","li","li-4",{"className":"leading-relaxed","children":["\n",["$","p","p-0",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":"SCRS (Society for Clinical Research Sites) -- Site coordinator burden surveys"}],"\n",["$","ul","ul-0",{"className":"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4","children":["\n",["$","li","li-0",{"className":"leading-relaxed","children":["$","a","a-0",{"href":"https://myscrs.org/","children":"https://myscrs.org/"}]}],"\n"]}],"\n"]}],"\n"]}]
51:["$","hr","hr-9",{"className":"my-8 border-neutral-100"}]
52:["$","h2","h2-10",{"className":"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28","children":"Summary Assessment"}]
53:["$","div","table-9",{"className":"my-6 overflow-x-auto rounded-lg border border-neutral-200","children":["$","table",null,{"className":"w-full text-sm","children":[["$","thead","thead-0",{"className":"border-b border-neutral-200 bg-neutral-50","children":["$","tr","tr-0",{"className":"bg-white","children":[["$","th","th-0",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Field"}],["$","th","th-1",{"className":"px-4 py-3 text-left font-medium text-neutral-700","children":"Key Number"}]]}]}],["$","tbody","tbody-0",{"className":"divide-y divide-neutral-100","children":[["$","tr","tr-0",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Problem Market Size"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$30B--$50B/year in trial delays and lost revenue"}]]}],["$","tr","tr-1",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Current Spend to Manage"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$15B--$20B/year (CRO recruitment + tech + services)"}]]}],["$","tr","tr-2",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Cost of Inaction"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$600K--$8M/day per delayed trial; 1--3 years of patent life lost"}]]}],["$","tr","tr-3",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Volume/Frequency"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~45K active trials; 80% delayed; 50--200 charts reviewed per enrolled patient"}]]}],["$","tr","tr-4",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Why Unsolved"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"EHR fragmentation, protocol complexity, regulatory barriers, site capacity"}]]}],["$","tr","tr-5",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Willingness to Pay"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$3K--$50K per patient; $2B--$3B VC/year flowing into trial tech"}]]}],["$","tr","tr-6",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Market Growth"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"6.5--18% CAGR depending on segment (AI matching fastest)"}]]}],["$","tr","tr-7",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Key Players"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":["IQVIA ($15.4B), Veeva ($2.4B), Medidata (",["$","del","del-0",{"children":"$$1.7B), Tempus ($693M), TriNetX ("}],"$$175M)"]}]]}]]}]]}]}]
54:["$","p","p-11",{"className":"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4","children":[["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Bottom line:"}]," This is a validated $30B+ problem with strong willingness to pay, clear budget holders (pharma clinical ops, CROs), and structural tailwinds (increasing trial complexity, FDA diversity mandates, AI maturity). The AI-powered patient matching subsegment is the fastest-growing at 14--18% CAGR, suggesting the market recognizes that technology -- not more manual labor -- is the path forward. The problem easily clears the $10B threshold."]}]
55:["$","div",null,{"className":"mt-16 flex flex-wrap items-center gap-4 border-t border-neutral-100 pt-8","children":[["$","$L2",null,{"href":"/reports/market-opportunity-research","className":"inline-flex items-center gap-1.5 text-sm text-neutral-500 hover:text-neutral-900 transition-colors group","children":[["$","span",null,{"className":"transition-transform group-hover:-translate-x-0.5","children":"â"}],"Back to AI Market Opportunity Research"]}],["$","span",null,{"className":"text-neutral-300","children":"Â·"}],["$","$L2",null,{"href":"/research","className":"inline-flex items-center gap-1.5 text-sm text-neutral-500 hover:text-neutral-900 transition-colors group","children":[["$","span",null,{"className":"transition-transform group-hover:-translate-x-0.5","children":"â"}],"Back to Research"]}]]}]
56:["$","$L6d",null,{"children":["$","$6e",null,{"name":"Next.MetadataOutlet","children":"$@6f"}]}]
57:["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"15--20%"}]
58:["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Insider Intelligence; Citeline"}]
59:["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Regulatory penalties for slow completion of post-market studies"}]
5a:["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"FDA warning letters; potential REMS issues"}]
5b:["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"FDA enforcement data"}]
5c:["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Total patients needed across all active trials"}]
5d:["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~5M--7M patients needed for enrollment globally"}]
5e:["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Industry estimate based on trial volumes"}]
5f:["$","tr","tr-9",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"% of US population aware of clinical trials"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"~16% aware, <5% participate"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"CISCRP perceptions survey (2023)"}]]}]
60:["$","tr","tr-10",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Site coordinator time spent on screening"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"20--40% of total work time"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"SCRS (Society for Clinical Research Sites)"}]]}]
61:["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Science 37"}]
62:["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Public (SNCE)"}]
63:["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"2021--2024"}]
64:["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Virtual/decentralized trials"}]
65:["$","tr","tr-8",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Huma Therapeutics"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$160M+"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"2023"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Decentralized trial platform"}]]}]
66:["$","tr","tr-9",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Inato"}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"$$20M Series B"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"2023"}],["$","td","td-3",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Community site trial matching marketplace"}]]}]
67:["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Healthcare data + patient matching"}]
68:["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Private; est. $100M--$150M ARR"}]
69:["$","tr","tr-7",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Deep 6 AI"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"NLP/AI for EHR-based patient matching"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Private; early-stage revenue"}]]}]
6a:["$","tr","tr-8",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Massive Bio"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"AI oncology trial matching for community sites"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Private; Series A stage"}]]}]
6b:["$","tr","tr-9",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Triomics"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"AI-powered oncology clinical trial matching"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Private; Series A ($15M, 2024)"}]]}]
6c:["$","tr","tr-10",{"className":"bg-white","children":[["$","td","td-0",{"className":"px-4 py-3 text-neutral-600 align-top","children":["$","strong","strong-0",{"className":"font-semibold text-neutral-800","children":"Inato"}]}],["$","td","td-1",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Marketplace connecting community sites with trials"}],["$","td","td-2",{"className":"px-4 py-3 text-neutral-600 align-top","children":"Private; Series B ($20M, 2023)"}]]}]
6f:null
